Immunotherapy in Prostate Cancer

被引：9

作者：

Sobol, Ilya ^{[1
]}

Thompson, R. H. ^{[1
]}

Dong, Haidong ^{[1
]}

Krco, Christopher ^{[1
]}

Kwon, Eugene D. ^{[1
]}

机构：

[1] Mayo Clin, Rochester, MN 55902 USA

来源：

CURRENT UROLOGY REPORTS | 2015年 / 16卷 / 06期

关键词：

Prostate cancer; Immunotherapy; PSA-TRICOM; Ipilimumab; SIPULEUCEL-T; DOUBLE-BLIND; PLACEBO; TRIAL; ACTIVATION; ANTIGEN; LIGAND;

D O I：

10.1007/s11934-015-0509-7

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Immunotherapy for the treatment of malignant neoplasms has made significant progress over the last 20 years. Multiple molecular targets and clinical agents have been developed recently, particularly in the field of metastatic adenocarcinoma of the prostate. Sipuleucel-T is currently the only FDA approved immunotherapy for prostate cancer. PSA-TRICOM (Prostvac) currently has a phase III randomized trial underway after a phase II trial showed an improvement in overall survival. Interestingly, both these agents showed improvement in overall survival with no measurable change in disease state, leading to significant controversy as the utility of these agents in prostate cancer. Ipilimumab revealed a benefit for a sub-cohort of men in a post-docetaxel group and is currently undergoing investigation in a pre-docetaxel group. There are a number of other targets such as PD-1 which have shown effectiveness in other neoplasms that will likely be investigated in the future for use in prostate cancer.

引用

页码：1 / 5

页数：5

共 15 条

[1] Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired [J].

Ahmadzadeh, Mojgan ;

Johnson, Laura A. ;

Heemskerk, Bianca ;

Wunderlich, John R. ;

Dudley, Mark E. ;

White, Donald E. ;

Rosenberg, Steven A. .

BLOOD, 2009, 114 (08) :1537-1544

[2] BTLA: a new inhibitory receptor with a B7-like ligand [J].

Carreno, BM ;

Collins, M .

TRENDS IN IMMUNOLOGY, 2003, 24 (10) :524-527

[3]

Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730

[4] The new B7s: Playing a pivotal role in tumor immunity [J].

Flies, Dallas B. ;

Chen, Lieping .

JOURNAL OF IMMUNOTHERAPY, 2007, 30 (03) :251-260

[5] Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma [J].

Hamid, Omid ;

Robert, Caroline ;

Daud, Adil ;

Hodi, F. Stephen ;

Hwu, Wen-Jen ;

Kefford, Richard ;

Wolchok, Jedd D. ;

Hersey, Peter ;

Joseph, Richard W. ;

Weber, Jeffrey S. ;

Dronca, Roxana ;

Gangadhar, Tara C. ;

Patnaik, Amita ;

Zarour, Hassane ;

Joshua, Anthony M. ;

Gergich, Kevin ;

Elassaiss-Schaap, Jeroen ;

Algazi, Alain ;

Mateus, Christine ;

Boasberg, Peter ;

Tumeh, Paul C. ;

Chmielowski, Bartosz ;

Ebbinghaus, Scot W. ;

Li, Xiaoyun Nicole ;

Kang, S. Peter ;

Ribas, Antoni .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (02) :134-144

[6] Integrated Data From 2 Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trials of Active Cellular Immunotherapy With Sipuleucel-T in Advanced Prostate Cancer [J].

Higano, Celestia S. ;

Schellhammer, Paul F. ;

Small, Eric J. ;

Burch, Patrick A. ;

Nemunaitis, John ;

Yuh, Lianng ;

Provost, Nicole ;

Frohlich, Mark W. .

CANCER, 2009, 115 (16) :3670-3679

[7] Improved Survival with Ipilimumab in Patients with Metastatic Melanoma [J].

Hodi, F. Stephen ;

O'Day, Steven J. ;

McDermott, David F. ;

Weber, Robert W. ;

Sosman, Jeffrey A. ;

Haanen, John B. ;

Gonzalez, Rene ;

Robert, Caroline ;

Schadendorf, Dirk ;

Hassel, Jessica C. ;

Akerley, Wallace ;

van den Eertwegh, Alfons J. M. ;

Lutzky, Jose ;

Lorigan, Paul ;

Vaubel, Julia M. ;

Linette, Gerald P. ;

Hogg, David ;

Ottensmeier, Christian H. ;

Lebbe, Celeste ;

Peschel, Christian ;

Quirt, Ian ;

Clark, Joseph I. ;

Wolchok, Jedd D. ;

Weber, Jeffrey S. ;

Tian, Jason ;

Yellin, Michael J. ;

Nichol, Geoffrey M. ;

Hoos, Axel ;

Urba, Walter J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (08) :711-723

[8] Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. [J].

Kantoff, Philip W. ;

Higano, Celestia S. ;

Shore, Neal D. ;

Berger, E. Roy ;

Small, Eric J. ;

Penson, David F. ;

Redfern, Charles H. ;

Ferrari, Anna C. ;

Dreicer, Robert ;

Sims, Robert B. ;

Xu, Yi ;

Frohlich, Mark W. ;

Schellhammer, Paul F. ;

Ahmed, T. ;

Amin, A. ;

Arseneau, J. ;

Barth, N. ;

Bernstein, G. ;

Bracken, B. ;

Burch, P. ;

Caggiano, V. ;

Chin, J. ;

Chodak, G. ;

Chu, F. ;

Corman, J. ;

Curti, B. ;

Dawson, N. ;

Deeken, J. F. ;

Dubernet, T. ;

Fishman, M. ;

Flanigan, R. ;

Gailani, F. ;

Garbo, L. ;

Gardner, T. ;

Gelmann, E. ;

George, D. ;

Godfrey, T. ;

Gomella, L. ;

Guerra, M. ;

Hall, S. ;

Hanson, J. ;

Israeli, R. ;

Jancis, E. ;

Jewett, M. A. S. ;

Kassabian, V. ;

Katz, J. ;

Klotz, L. ;

Koeneman, K. ;

Koh, H. ;

Kratzke, R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (05) :411-422

[9] Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer [J].

Kantoff, Philip W. ;

Schuetz, Thomas J. ;

Blumenstein, Brent A. ;

Glode, L. Michael ;

Bilhartz, David L. ;

Wyand, Michael ;

Manson, Kelledy ;

Panicali, Dennis L. ;

Laus, Reiner ;

Schlom, Jeffrey ;

Dahut, William L. ;

Arlen, Philip M. ;

Gulley, James L. ;

Godfrey, Wayne R. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) :1099-1105

[10]

Khattri R, 1999, J IMMUNOL, V162, P5784

← 1 2 →